PCSK9 and familial hypercholesterolemia: Elevated levels of PCSK9, or “gain of function” variants, have been associated with an increased risk of cardiovascular disease and familial hypercholesterolemia (Libby & Tokgözoğlu, 2022; Shapiro et al., 2018), while “loss of function” mutations are associated with low LDL‐C levels, a decreased risk of cardiovascular events and, notably, no associated adverse consequences (Cohen et al., 2006; Zhao et al., 2006).